Effects of haloperidol inhalation on MK-801- and memantine-induced locomotion in mice

References

• Abbott A. Schizophrenia: the drug deadlock. Nature. 2010;468(7321):158–11.
   Google Scholar
• Nutt DJ, Attridge J. CNS drug development in Europe–past progress and future challenges. Neurobiol Dis. 2014;61:6–20.
   Google Scholar
• Alavijeh MS, Chishty M, Qaiser MZ, et al. Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery. NeuroRx. 2005;2(4):554–571.
   Google Scholar
• Crowe TP, Greenlee MHW, Kanthasamy AG, et al. Mechanism of intranasal drug delivery directly to the brain. Life Sci. 2018;195:44–52.
   Google Scholar
• Djupesland PG, Mahmoud RA, Messina JC. Accessing the brain: the nose may know the way. J Cereb Blood Flow Metab. 2013;33(5):793–794.
   Google Scholar
• Pardeshi CV, Rajput PV, Belgamwar VS, et al. Novel surface modified solid lipid nanoparticles as intranasal carriers for ropinirole hydrochloride: application of factorial design approach. Drug Deliv. 2013;20(1):47–56.
   Google Scholar
• Bastir M, Rosas A, Gunz P, et al. Evolution of the base of the brain in highly encephalized human species. Nat Commun. 2011;2:588.
   Google Scholar
• Chapman CD, Frey WH 2nd, Craft S, et al. Intranasal treatment of central nervous system dysfunction in humans. Pharm Res. 2013;30(10):2475–2484.
   Google Scholar
• Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev. 2012;64(7):614–628.
   Google Scholar
• Eller N, Kollenz CJ, Hitzenberger G. A comparative study of pharmacodynamics and bioavailability of 2 different desmopressin nasal sprays. Int J Clin Pharmacol Ther. 1998;36(3):139–145.
   Google Scholar
• Illum L. Nasal drug delivery–possibilities, problems and solutions. J Control Release. 2003;87(1–3):187–198.
   Google Scholar
• Kapoor M, Cloyd JC, Siegel RA. A review of intranasal formulations for the treatment of seizure emergencies. J Control Release. 2016;237:147–159.
   Google Scholar
• Shinde RL, Bharkad GP, Devarajan PV. Intranasal microemulsion for targeted nose to brain delivery in neurocysticercosis: role of docosahexaenoic acid. Eur J Pharm Biopharm. 2015;96:363–379.
   Google Scholar
• McGrath J, Saha S, Chant D, et al. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30:67–76.
   Google Scholar
• Owen MJ, Sawa A, Mortensen PB. Schizophrenia. Lancet. 2016;388(10039):86–97.
   Google Scholar
• Hashimoto K. Targeting of NMDA receptors in new treatments for schizophrenia. Expert Opin Ther Targets. 2014;18(9):1049–1063.
   Google Scholar
• Hashimoto K, Malchow B, Falkai P, et al. Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci. 2013;263(5):367–377.
   Google Scholar
• Hashimoto K, Sudo T, Hirano M, et al. Efficacy and safety of zotepine for patients with treatment-resistant schizophrenia. Schizophr Res. 2006;87(1–3):332–333.
   Google Scholar
• Hashimoto K, Fujita Y, Horio M, et al. Co-administration of a D-amino acid oxidase inhibitor potentiates the efficacy of D-serine in attenuating prepulse inhibition deficits after administration of dizocilpine. Biol Psychiatry. 2009;65(12):1103–1106.
   Google Scholar
• Karasawa J, Hashimoto K, Chaki S. D-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats. Behav Brain Res. 2008;186(1):78–83.
   Google Scholar
• Meltzer HY, Horiguchi M, Massey BW. The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment. Psychopharmacology (Berl). 2011;213(2–3):289–305.
   Google Scholar
• Okamura N, Hashimoto K, Shimizu E, et al. Adenosine A1 receptor agonists block the neuropathological changes in rat retrosplenial cortex after administration of the NMDA receptor antagonist dizocilpine. Neuropsychopharmacology. 2004;29(3):544–550.
   Google Scholar
• Rajagopal L, Massey BW, Huang M, et al. The novel object recognition test in rodents in relation to cognitive impairment in schizophrenia. Curr Pharm Des. 2014;20(31):5104–5114.
   Google Scholar
• Rogóż Z. Effect of combined treatment with mirtazapine and risperidone on the MK-801-induced changes in the object recognition test in mice. Pharmacol Rep. 2013;65(5):1401–1406.
   Google Scholar
• Zhang L, Shirayama Y, Iyo M, et al. Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine. Neuropsychopharmacology. 2007;32(9):2004–2010.
   Google Scholar
• Ouagazzal A, Nieoullon A, Amalric M. Effects of dopamine D1 and D2 receptor blockade on MK-801-induced hyperlocomotion in rats. Psychopharmacology (Berl). 1993;111(4):427–434.
   Google Scholar
• Bubser M, Bridges TM, Dencker D, et al. Selective activation of M4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodents. ACS Chem Neurosci. 2014;5(10):920–942.
   Google Scholar
• Enomoto T, Ishibashi T, Tokuda K, et al. Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats. Behav Brain Res. 2008;186(2):197–207.
   Google Scholar
• Park SJ, Lee Y, Oh HK, et al. Oleanolic acid attenuates MK-801-induced schizophrenia-like behaviors in mice. Neuropharmacology. 2014;86:49–56.
   Google Scholar
• Parsons CG, Stöffler A, Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system–too little activation is bad, too much is even worse. Neuropharmacology. 2007;53(6):699–723.
   Google Scholar
• Rammes G, Rupprecht R, Ferrari U, et al. The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner. Neurosci Lett. 2001;306(1–2):81–84.
   Google Scholar
• Reiser G, Binmöller FJ, Koch R. Memantine (1-amino-3,5-dimethyladamantane) blocks the serotonin-induced depolarization response in a neuronal cell line. Brain Res. 1988;443(1–2):338–344.
   Google Scholar
• Aracava Y, Pereira EF, Maelicke A, et al. Memantine blocks alpha7* nicotinic acetylcholine receptors more potently than n-methyl-D-aspartate receptors in rat hippocampal neurons. J Pharmacol Exp Ther. 2005;312(3):1195–1205.
   Google Scholar
• Seeman P, Caruso C, Lasaga M. Memantine agonist action at dopamine D2High receptors. Synapse. 2008;62(2):149–153.
   Google Scholar
• Kitanaka N, Kitanaka J, Hall FS, et al. Psychotomimetic-like behavioral effects of memantine in the mouse. Biomed Pharmacother. 2018;100:116–123.
   Google Scholar
• Yatham LN, Goldstein JM, Vieta E, et al. Atypical antipsychotics in bipolar depression: potential mechanisms of action. J Clin Psychiatry. 2005;66(Suppl 5):40–48.
   Google Scholar
• Mori T, Ito S, Kita T, et al. Effects of dopamine- and serotonin-related compounds on methamphetamine-induced self-injurious behavior in mice. J Pharmacol Sci. 2004;96(4):459–464.
   Google Scholar
• Yael D, Zeef DH, Sand D, et al. Haloperidol-induced changes in neuronal activity in the striatum of the freely moving rat. Front Syst Neurosci. 2013;7:110.
   Google Scholar
• Wiley JL, Evans RL. Evaluation of age and sex differences in locomotion and catalepsy during repeated administration of haloperidol and clozapine in adolescent and adult rats. Pharmacol Res. 2008;58(3–4):240–246.
   Google Scholar
• Murdin L, Hussain K, Schilder AGM. Betahistine for symptoms of vertigo. Cochrane Database of Systematic Reviews 2016, Issue 6. Art. No.: CD010696.
   Google Scholar
• Gbahou F, Davenas E, Morisset S, et al. Effects of betahistine at histamine H3 receptors: mixed inverse agonism/agonism in vitro and partial inverse agonism in vivo. J Pharmacol Exp Ther. 2010;334(3):945–954.
   Google Scholar
• Tighilet B, Trottier S, Mourre C, et al. Betahistine dihydrochloride interaction with the histaminergic system in the cat: neurochemical and molecular mechanisms. Eur J Pharmacol. 2002;446(1–3):63–73.
   Google Scholar
• Bygrave AM, Masiulis S, Nicholson E, et al. Knockout of NMDA-receptors from parvalbumin interneurons sensitizes to schizophrenia-related deficits induced by MK-801. Transl Psychiatry. 2016;6(4):e778.
   Google Scholar
• Gray L, van den Buuse M, Scarr E, et al. Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: association with N-methyl-D-aspartic acid receptor up-regulation. Int J Neuropsychopharmacol. 2009;12(1):45–60.
   Google Scholar
• O’Neill MF, Hicks CA, Shaw G, et al. Effects of 5-hydroxytryptamine2 receptor antagonism on the behavioral activation and immediate early gene expression induced by dizocilpine. J Pharmacol Exp Ther. 1998;287(3):839–846.
   Google Scholar
• Patel N, Hitzemann B, Hitzemann R. Genetics, haloperidol, and the Fos response in the basal ganglia: a comparison of the C57BL/6J and DBA/2J inbred mouse strains. Neuropsychopharmacology. 1998;18(6):480–491.
   Google Scholar
• Ueno H, Suemitsu S, Murakami S, et al. Behavioural effects of inhalation exposure to dizocilpine (MK-801) in mice. Biomed Pharmacother. 2019;117:109038.
   Google Scholar
• Wolf ME, White FJ, Hu XT. Behavioral sensitization to MK-801 (dizocilpine): neurochemical and electrophysiological correlates in the mesoaccumbens dopamine system. Behav Pharmacol. 1993;4(4):429–442.
   Google Scholar
• Sukhanov IM, Zakharova ES, Danysz W, et al. Effects of NMDA receptor channel blockers, MK-801 and memantine, on locomotor activity and tolerance to delay of reward in wistar-kyoto and spontaneously hypertensive rats. Behav Pharmacol. 2004;15(4):263–271.
   Google Scholar
• Bubenikova-Valesova V, Stuchlik A, Svoboda J, et al. Risperidone and ritanserin but not haloperidol block effect of dizocilpine on the active allothetic place avoidance task. Proc Natl Acad Sci U S A. 2008;105(3):1061–1066.
   Google Scholar
• Irifune M, Shimizu T, Nomoto M, et al. Involvement of N-methyl-D-aspartate (NMDA) receptors in noncompetitive NMDA receptor antagonist-induced hyperlocomotion in mice. Pharmacol Biochem Behav. 1995;51(2–3):291–296.
   Google Scholar
• Song JC, Seo MK, Park SW, et al. Differential effects of olanzapine and haloperidol on MK-801-induced memory impairment in mice. Clin Psychopharmacol Neurosci. 2016;14(3):279–285.
   Google Scholar
• Ziólkowska B, Höllt V. The NMDA receptor antagonist MK-801 markedly reduces the induction of c-fos gene by haloperidol in the mouse striatum. Neurosci Lett. 1993;156(1–2):39–42.
   Google Scholar
• Feinberg I, Campbell IG. Haloperidol potentiates the EEG slowing of MK-801 despite blocking its motor effects: implications for the PCP model of schizophrenia. Neuroreport. 1998;9(10):2189–2193.
   Google Scholar
• Miller JL, Ashford JW, Archer SM, et al. Comparison of intranasal administration of haloperidol with intravenous and intramuscular administration: a pilot pharmacokinetic study. Pharmacotherapy. 2008;28(7):875–882.
   Google Scholar
• Katare YK, Daya RP, Sookram Gray C, et al. brain targeting of a water insoluble antipsychotic drug haloperidol via the intranasal route using PAMAM dendrimer. Mol Pharm. 2015;12(9):3380–3388.
   Google Scholar
• Thorne RG, Pronk GJ, Padmanabhan V, et al. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience. 2004;127(2):481–496.
   Google Scholar
• Dhuria SV, Hanson LR, Frey WH 2nd. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci. 2010;99(4):1654–1673.
   Google Scholar
• Polese G, Winlow W, Di Cosmo A. Dose-dependent effects of the clinical anesthetic isoflurane on Octopus vulgaris: a contribution to cephalopod welfare. J Aquat Anim Health. 2014;26(4):285–294.
   Google Scholar
• Zhou J, Iwasaki S, Yamakage M. Time- and dose-dependent effects of desflurane in sensitized airways. Anesth Analg. 2017;124(2):465–471.
   Google Scholar